XML 72 R51.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment Information Segment Information (Tables)
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Schedule of Additional Segment Information Disclosures [Table Text Block]
Depreciation and software amortization expense included in our segment profits was as follows:
 
2016
 
2015
 
2014
Human pharmaceutical products
$
723.4

 
$
720.7

 
$
790.0

Animal health products
89.9

 
80.8

 
58.8

Total depreciation expense and software amortization included in segment profits
$
813.3


$
801.5


$
848.8
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
 
 
 
 
2016
 
2015
 
2014
Segment revenue—to unaffiliated customers:
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
 
 
 
 
 
 
Endocrinology:
 
 
 
 
 
 
Humalog®
 
$
2,768.8

 
$
2,841.9

 
$
2,785.2

Forteo®
 
1,500.0

 
1,348.3

 
1,322.0

Humulin®
 
1,365.9

 
1,307.4

 
1,400.1

Trulicity®
 
925.5

 
248.7

 
10.2

Trajenta
 
436.6

 
356.8

 
328.8

Evista
 
172.4

 
237.3

 
419.8

Other Endocrinology
 
913.6

 
696.4

 
672.9

Total Endocrinology
 
8,082.8

 
7,036.8

 
6,939.0

 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
Alimta
 
2,283.3

 
2,493.1

 
2,792.0

Erbitux
 
687.0

 
485.0

 
373.3

Cyramza®
 
614.1

 
383.8

 
75.6

Other Oncology
 
137.4

 
147.9

 
152.1

Total Oncology
 
3,721.8

 
3,509.8

 
3,393.0

 
 
 
 
 
 
 
Cardiovascular:
 
 
 
 
 
 
Cialis
 
2,471.6

 
2,310.7

 
2,291.0

Effient
 
535.2

 
523.0

 
522.2

Other Cardiovascular
 
218.6

 
234.3

 
240.3

Total Cardiovascular
 
3,225.4

 
3,068.0

 
3,053.5

 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
Cymbalta(1)
 
930.5

 
1,027.6

 
1,614.7

Strattera
 
854.7

 
784.0

 
738.5

Zyprexa
 
725.3

 
940.3

 
1,037.3

Other Neuroscience
 
209.8

 
183.5

 
206.0

Total Neuroscience
 
2,720.3


2,935.4


3,596.5

 
 
 
 
 
 
 
Other human pharmaceutical products
 
313.6

 
227.7

 
287.0

Total human pharmaceutical products
 
18,063.9


16,777.7


17,269.0

Animal health products
 
3,158.2

 
3,181.0

 
2,346.6

Revenue
 
$
21,222.1

 
$
19,958.7

 
$
19,615.6

 
 
 
 
 
 
 
 
 
 
 
2016
 
2015
 
2014
Segment profits:
 
 
 
 
 
 
Human pharmaceutical products
 
$
4,010.0

 
$
4,026.7

 
$
3,604.6

Animal health products
 
663.7

 
597.9

 
621.8

Total segment profits
 
$
4,673.7

 
$
4,624.6

 
$
4,226.4

 
 
 
 
 
 
 
Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
Segment profits
 
$
4,673.7

 
$
4,624.6

 
$
4,226.4

Other profits (losses):
 
 
 
 
 
 
Amortization of intangible assets (Note 8)
 
(683.3
)
 
(626.2
)
 
(530.2
)
Asset impairment, restructuring, and other special charges (Note 5)
 
(382.5
)
 
(367.7
)
 
(468.7
)
Venezuela charge (Note 17)
 
(203.9
)
 
—

 
—

Acquired in-process research and development (Notes 3 and 4)
 
(30.0
)
 
(535.0
)
 
(200.2
)
Inventory fair value adjustment related to Novartis AH (Note 3)
 
—

 
(153.0
)
 
—

Debt repurchase charges, net(2) (Note 10)
 
—

 
(152.7
)
 
—

U.S. Branded Prescription Drug Fee
 
—

 
—

 
(119.0
)
Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4)
 
—

 
—

 
92.0

Consolidated income before taxes
 
$
3,374.0

 
$
2,790.0

 
$
3,000.3
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
 
 
 
 
2016
 
2015
 
2014
Geographic Information
 
 
 
 
 
 
Revenue—to unaffiliated customers(1):
 
 
 
 
 
 
United States
 
$
11,506.2

 
$
10,097.4

 
$
9,134.1

Europe
 
3,768.1

 
3,943.6

 
4,506.7

Japan
 
2,330.9

 
2,033.1

 
2,027.1

Other foreign countries
 
3,616.9

 
3,884.6

 
3,947.7

Revenue
 
$
21,222.1

 
$
19,958.7

 
$
19,615.6

 
 
 
 
 
 
 
Long-lived assets(2):
 
 
 
 
 
 
United States
 
$
4,984.6

 
$
4,576.8

 
$
4,566.2

Europe
 
2,140.7

 
2,306.4

 
2,401.5

Japan
 
92.4

 
89.2

 
80.4

Other foreign countries
 
1,776.8

 
1,724.2

 
1,499.1

Long-lived assets
 
$
8,994.5

 
$
8,696.6

 
$
8,547.2


(1) Revenue is attributed to the countries based on the location of the customer.
(2) Long-lived assets consist of property and equipment, net, and certain sundry assets.